029-83533393
   info@TaiBSbio.com
 
组织芯片,组织微阵列
 
UBD902多病理类型膀胱癌及膀胱组织组合芯片,附病理分级、TNM和临床分期,90例/90点
点 数90例 数90
行 数9列 数10
点直径(mm)1.5厚度(µm)5.0
组织阵列类型石蜡包埋种 属人类
QA/QCH&E and IHC confirmed
ApplicationsRoutine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.
Notes1.Please keep the slides at 4 ℃ after receiving, and make experiment within 3 months will be better.

2.Bake the slides for 30 minutes at 60℃ before the experiment;

3.Please choose a gentle repair method to avoid tissue detachment.

产品名:UBD902
 
多病理类型膀胱癌及膀胱组织组合微阵列芯片,包含46例尿路上皮癌,17例腺癌,13例鳞状细胞癌,1例未分化癌,2例小细胞癌,1例癌肉瘤,10例边缘或癌旁膀胱组织(其中2例与癌匹配),一块一点
 
 
询价  Tel: 029-83533393
 
下载说明书
 
 
Legend:
Bla
-Bladder
 
Malignant (*)
 
Malignant (I)
 
Malignant (II)
 
Malignant (IIIA)
 
Malignant (IIIB)
TISSUE  ARRAYS UBD902
1
2
3
4
5
6
7
8
9
10
A
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
B
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
C
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
D
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
E
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
F
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
G
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
H
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
I
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
BLA
 
PosNoAgeSexOrgan_Anatomic_SitePathology_diagnosisGradeTNMStageTypeTumor SizeisBackUp
A1172MBladderLow-grade urothelial carcinoma*T1N0M0IMalignant5*5*2.5N
A2250MBladderLow-grade urothelial carcinoma*T2N0M0IIMalignant3*2*1N
A3371MBladderLow-grade urothelial carcinoma*T2bN0M0IIMalignant4.5*3*2N
A4470MBladderLow-grade urothelial carcinoma*T1N0M0IMalignant5*4*4N
A5558MBladderLow-grade urothelial carcinoma*T1N0M0IMalignant8*7*5N
A6659FBladderLow-grade urothelial carcinoma*T1N0M0IMalignant4*3.5*3.5N
A7737FBladderLow-grade urothelial carcinoma*T1N0M0IMalignant5*5*2.5N
A8867MBladderLow-grade urothelial carcinoma*T2aN0M0IIMalignant3*1*0.5N
A9951MBladderLow-grade urothelial carcinoma*T1N0M0IMalignant6*4*2N
A101079FBladderLow-grade urothelial carcinoma*T2N0M0IIMalignant*N
B11145FBladderLow-grade urothelial carcinoma*T1N0M0IMalignant3*2*1.5N
B21261MBladderLow-grade urothelial carcinoma*T2N0M0IIMalignant*N
B31356FBladderLow-grade urothelial carcinoma*T2N0M0IIMalignant6*5*0.5N
B41470MBladderLow-grade urothelial carcinoma*T2N0M0IIMalignant10*7*5N
B51555MBladderLow-grade urothelial carcinoma*T3bN0M0IIIAMalignant*N
B61665MBladderLow-grade urothelial carcinoma*T2N0M0IIMalignant*N
B71752MBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant6*5*2N
B81842MBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant*N
B91943FBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant*N
B102057FBladderHigh grade urothelial carcinoma*T3N0M0IIIAMalignant6*4*4N
C12156MBladderHigh grade urothelial carcinoma*T3N0M0IIIAMalignant*N
C22233MBladderHigh grade urothelial carcinoma*T3N1M0IIIAMalignant*N
C32370FBladderHigh grade urothelial carcinoma*T3aM0N0IIIAMalignant5.0*5.0*2.0N
C42453MBladderHigh grade urothelial carcinoma (interstitial)*T3bN0M0IIIAMalignant11*8*4N
C52544MBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant*N
C62670MBladderHigh grade urothelial carcinoma*T2bN0M0IIMalignant5*4*3N
C72742MBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant3*2*1N
C82860FBladderHigh grade urothelial carcinoma*T3bN0M0IIIAMalignant3*2N
C92935MBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant*N
C103066MBladderHigh grade urothelial carcinoma*T3bN0M0IIIAMalignant*N
D13180MBladderHigh grade urothelial carcinoma*T2bN0M0IIMalignant*N
D23250FBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant3*2*2N
D33370MBladderHigh grade urothelial carcinoma*T1N0M0IMalignant5*3*2N
D43461MBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant*N
D53545FBladderHigh grade urothelial carcinoma*T3N0M0IIIAMalignant10*7*7N
D63656MBladderLow-grade urothelial carcinoma*T2N0M0IIMalignant3*2*1N
D73736MBladderLow-grade urothelial carcinoma*T2bN0M0IIMalignant*N
D83865MBladderHigh grade urothelial carcinoma*T1N0M0IMalignant3*2*1N
D93973FBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant3*2*2N
D104078FBladderHigh grade urothelial carcinoma*T1N0M0IMalignant7*5*2N
E14138MBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant10*8*3N
E24267MBladderHigh grade urothelial carcinoma*T3N0M0IIIAMalignant*N
E34365MBladderHigh grade urothelial carcinoma*T2N0M0IIMalignant*N
E44452MBladderHigh grade urothelial carcinoma*T4aN0M0IIIAMalignant*N
E54545MBladderHigh grade urothelial carcinoma*T3bN0M0IIIAMalignant*N
E64636FBladderHigh grade urothelial carcinoma*T1N0M0IMalignant5.0N
E74774FBladderAdenocarcinoma2T1N0M0IMalignant3*2*2N
E84860MBladderAdenocarcinoma2T2N1M0IIIAMalignant*N
E94941MBladderAdenocarcinoma2T2N0M0IIMalignant*N
E105070MBladderAdenocarcinoma2T3N0M0IIIAMalignant*N
F15158MBladderAdenocarcinoma with necrosis2T2N0M0IIMalignant*N
F25257MBladderAdenocarcinoma2T1N0M0IMalignant*N
F35348FBladderAdenocarcinoma2T3N0M0IIIAMalignant10*6*3N
F45476MBladderAdenocarcinoma2--3T4N0M0IIIAMalignant*N
F55550MBladderAdenocarcinoma3T3N0M0IIIAMalignant6*5*2.5N
F65643MBladderAdenocarcinoma3T3aM0N0IIIAMalignant10*7*6N
F75753MBladderAdenocarcinoma3T3N1M0IIIAMalignant*N
F85865MBladderAdenocarcinoma3T4N0M0IIIAMalignant2.5*1.5*1N
F95970MBladderAdenocarcinoma3T2bN0M0IIMalignant*N
F106058MBladderAdenocarcinoma3T2N0M0IIMalignant4.5N
G16157MBladderMucinous adenocarcinoma2T2N0M0IIMalignant5.0*4.5*3N
G26257MBladderMucinous adenocarcinoma3T2aN0M0IIMalignant5*3*2N
G36353FBladderMucinous adenocarcinoma3T3N0M0IIIAMalignant*N
G46453MBladderSquamous cell carcinoma1T2N0M0IIMalignant4.5*4.5*3N
G56546MBladderSquamous cell carcinoma1T2aN0M0IIMalignant*N
G66651MBladderSquamous cell carcinoma2T2bN2M0IIIBMalignant*N
G76746FBladderSquamous cell carcinoma2T3N0M0IIIAMalignant*N
G86868MBladderSquamous cell carcinoma2T3aM0N0IIIAMalignant6*3.5*3N
G96966FBladderSquamous cell carcinoma2T3N1M0IIIAMalignant*N
G107068MBladderSquamous cell carcinoma2T3bN0M0IIIAMalignant6*5.5N
H17151MBladderSquamous cell carcinoma2T3aM0N0IIIAMalignant*N
H27272MBladderSquamous cell carcinoma2--3T3bN0M0IIIAMalignant6*4*3N
H37365MBladderSquamous cell carcinoma3T3bN0M0IIIAMalignant6*4N
H47457MBladderSquamous cell carcinoma3T3aM0N0IIIAMalignant*N
H57552MBladderSquamous cell carcinoma3T3N0M0IIIAMalignant*N
H67675MBladderSquamous cell carcinoma3T2N1M0IIIAMalignant*N
H77757MBladderUndifferentiated carcinoma*T2N1M0IIIAMalignant*N
H87850FBladderSmall cell carcinoma*T2N1M0IIIAMalignant*N
H97949FBladderSmall cell carcinoma*T3N1M0IIIAMalignant*N
H108067MBladderCarcinosarcoma*T3N1M0IIIAMalignant5*4*4N
I18155MBladderAdjacent normal bladder tissue***Malignant*N
I28273MBladderCancer adjacent bladder tissue***Malignant10*7*6N
I38351MBladderAdjacent normal bladder tissue***Malignant3*1.5N
I48446FBladderCancer adjacent bladder tissue of No.67***Malignant6*5*2.5N
I58553MBladderAdjacent normal bladder tissue***Malignant*N
I68654FBladderCancer adjacent bladder tissue***Malignant2.5*1.5*1N
I78775MBladderAdjacent normal bladder tissue of No.76***Malignant*N
I88878FBladderAdjacent normal bladder tissue***Malignant*N
I98971MBladderCancer adjacent bladder tissue***Malignant*N
I109063MBladderAdjacent normal bladder tissue***Malignant*N
Tissue Marker
 
 
西安泰博斯生物科技有限公司

 
联系我们
地址:陕西西安市灞桥区长乐东路2999号
电话:029-83533393, 17792711553,
电子邮箱:taibsbio@163.com
QQ:3144647811
微信号:13002913390
邮政编码:710075
关于我们
西安泰博斯生物科技有限公司主要经营组织芯片的研发、销售,加工定制和与组织芯片有关的生物技术服务项目。公司目前拥有专业的病理医生和技术研发团队,并且具有庞大的组织标本库。样本库中组织微阵列种类多,病理类型齐全,同时根据客户需求情况进行制作加工新的组织微阵列,尽量满足每一个客户的需求。公司一直秉承着“认真、严谨、负责”的工作态度,致力于为广大客户提供质量好的产品和优质的服务。

更多详情